News and press releases covering LASEROPTEK devices and technology are available in this corner.

Keep up to date with our global presence in the medical and aesthetics here.

  • LASEROPTEK Co., Ltd. Receives FDA 510(k) With Expanded Aesthetic Indications for its PicoLO™ Picosecond Nd:YAG Laser

    Nd:YAG True Picosecond Pulse Laser With Expanded Indications for Treatment of Benign Pigmented Lesions, Acne Scars, and Wrinkles SEOUL, Republic of Korea, April 23, 2021 / LASEROPTEK CO. LTD. / --  LASEROPTEK Co., Ltd., a developer and manufacturer of world-class laser devices for aesthetic and medical dermatology applications, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) expanding the indications for its PicoLO™ picosecond pulse Nd:YAG laser to include treatment of benign pigmented lesions, acne scars, and wrinkles. This 510(k) clearance represents a significant milestone in PicoLO’s evolution as a world-class picosecond pulse Nd:YAG laser delivering powerful and consistent photoacoustic generated Laser Induced Optical Breakdown (LIOB) within the skin to quickly and effectively fracture and finely fragment artificial and natural pigments such as in tattoos and benign pigmented lesions. PicoLO’s unique handpiece technology coupled with industry-leading energy and pulse duration stability provides clinicians the capability to selectively deliver LIOB to the dermis, upper dermis, and epidermis as desired. This LIOB depth control enables targeted micro wounding; catalyzing the body’s wound healing response consequently facilitating neocollagenesis and neoelastinogenesis that safely and effectively reduces the appearance of scars and wrinkles. LASEROPTEK’s President and CEO, CJ Lee, stated “The newly FDA-cleared indications for benign pigmented lesions, acne scars and wrinkles, added to PicoLO’s current indication for tattoo removal, marks PicoLO’s substantial progress in creating new opportunities for U.S. clinicians to deliver a wide range of safe, comfortable, and efficacious cosmetic laser procedures. This represents a further testament to our commitment to advance the development of laser-based energy devices bringing value to dermatologists, plastic surgeons, medical aesthetic practitioners, and their patients on a global basis,” added Mr. Lee. Dr. William Philip Werschler, MD, FAAD, commented “PicoLO’s new 510(k) with expanded cosmetic indications opens the door for cost-effective, advanced picosecond pulse laser skin rejuvenation treatments. We are excited to work with LASEROPTEK to offer PicoLO procedures to our patients at Spokane Dermatology and Werschler Aesthetics.” To learn more about PicoLO and the entire suite of LASEROPTEK aesthetic and medical dermatology laser systems, please contact Jayson Jonsson of Gale Force Aesthetics, LLC at +1(925) 705-6206 or visit www.laseroptek.com. About LASEROPTEK Co., Ltd. LASEROPTEK is a global, technology-driven medical device company with a focus on aesthetic and medical lasers. Founded in 2000 and with in-house R&D capabilities, LASEROPTEK develops, manufactures, and markets safe, stable, and high-quality laser systems merging advanced laser technology with clinical efficacy. Media Contacts Helena Lee, Marketing Director jylee@laseroptek.com +82 2-2135-1990 Christopher Dalton, Vice President dalton.christopher@laseroptek.com +1(619) 609-4757 Read the Press Release here: https://rebrand.ly/zj2bz55FDA510k

    VIEW MORE +
  • LASEROPTEK Receives PMDA Approval for PALLAS™

    SEOUL, Republic of Korea – January 6, 2021 – LASEROPTEK Co., Ltd. has announced PMDA approval for its PALLAS™ laser system. The PMDA, or Pharmaceuticals and Medical Devices Agency, is a pharmaceutical regulatory authority in Japan renowned for its strict licensing procedures. With that, PALLAS is the first-ever Korean device to be approved by the PMDA for treating chronic skin conditions including vitiligo, psoriasis, and atopic dermatitis. Most recently, LASEROPTEK’s PicoLO, HELIOS III, and LOTUS III laser systems also obtained licensing from Australia’s own regulatory body for medicines, medical devices, and diagnostics, the Therapeutic Good Administration (TGA). PALLAS is the world’s first solid-state Nd:YAG laser system that integrates 308nm and 311nm wavelengths designed to treat such conditions both effectively and safely – without the use of anesthetics – for people of all ages. PALLAS also reduces the cost of maintenance for users while operating the device daily. Following PMDA approval of PALLAS, C.J. Lee, CEO of LASEROPTEK, said the company is confident it can accelerate entry into global medical and aesthetic markets with cutting-edge laser systems supported by strong roots in R&D, and firm establishment of the company’s global network infrastructure. The clinical efficacies of PALLAS are featured in the Journal of American Medical Association (JAMA) Dermatology, Journal of the American Academy of Dermatology (JAAD), Wiley’s Photodermatology, Photoimmunology & Photomedicine, among other prestigious publications. About LASEROPTEK Co., Ltd. LASEROTPEK is a global developer and manufacturer of aesthetic and medical laser systems. Founded in 2000 with in-house R&D capabilities, LASEROPTEK offers safe, stable, and high-quality laser systems merging together advanced laser technologies with clinical efficacy. To learn more about PALLAS and the entire lineup of LASEROPTEK lasers, please visit us at www.laseroptek.com or email us at marketing@laseroptek.com.

    VIEW MORE +
  • LASEROPTEK Receives CE Mark for PicoLO Premium™, Opening the Door to the EU Market

    SEOUL, Republic of Korea - February 19, 2021 - A global developer and manufacturer of aesthetic and medical laser systems, LASEROPTEK Co., Ltd. is pleased to announce European CE Marking for its latest Picosecond Nd: YAG laser, PicoLO Premium™. Representing a significant upgrade from PicoLO which launched in 2018, PicoLO Premium takes efficacy and user convenience to the next level via a powerful lineup of next-generation handpieces. Handpieces include both a 1064nm and a 532nm Diffractive Optical Element (DOE) based fractional handpieces, a Collimator handpiece, a Zoom handpiece, and an exclusive S20 handpiece with a wider spot size for fast and efficient treatments. Boasting powerful and stable beam profiles, PicoLO Premium’s DOE fractional handpieces are also upgraded with a new look and branding. The “Dia FX®” 1064nm  ‘S’ handpiece enables highly delicate and defined area treatments with a new level of precision and efficacy. It also features a new and simple twist-and-treat function that allows users to quickly and easily select from three distinct laser energy penetration depths. Efficacious picosecond pulses targeting the deep dermis, upper dermis, and epidermis can now be accurately and repeatedly delivered helping clinicians create amazing outcomes. Additionally, the Dia FX 1064 handpiece also features two spot sizes for treating indications that require precision and customization. Commenting on PicoLO Premium’s CE Mark and incorporation into the company’s extensive line-up of cutting-edge laser systems, C.J. Lee, CEO of LASEROPTEK  said “PicoLO Premium’s CE Mark allows us to export a world-class laser that meets the exceptional standards and demands of European clinicians in their  respective regions.” “The company is well-equipped to face the rapidly changing medical and aesthetic market head-on as a pioneer in Europe and other global regions,” added Mr. Lee. Evidencing PicoLO Premium’s treatment efficacy for various indications, a recent study published in the Journal of European Academy of Dermatology and  Venereology concluded that the PicoLO Premium with the Dia FX 1064nm handpiece was proven to be more effective in treating acne scars with noticeable clinical improvements to skin pores and texture when compared to the non-ablative 1550nm Er: Glass laser. About LASEROPTEK Co., Ltd. LASEROTPEK is a global developer and manufacturer of aesthetic and medical laser systems. Founded in 2000 with in-house R&D capabilities, LASEROPTEK offers safe, stable, and high-quality laser systems merging together advanced laser technologies with clinical efficacy. To learn more about the new PicoLO Premium and the entire lineup of LASEROPTEK lasers, please visit us at www.laseroptek.com or email us at marketing@laseroptek.com. Media Contacts  Helena Lee, Marketing Director jylee@laseroptek.com +82 2-2135-1990 Kyung Lee, Marketing Manager kyung@laseroptek.com +82 2-3474-1892 Read the Press Release here: https://rebrand.ly/c2vuhu3PIPce  

    2021.02.19

  • Founder of LASEROPTEK HONG-CHU won the 2020 Industrial Technology Award of the Month with PicoLO laser

    Founder of LASEROPTEK HONG-CHU won the 2020 Industrial Technology Award of the Month with PicoLO laser. Awarded in the commercialization technology category for the development of a diagnosis/treatment system based on a wavelength tunable ultra-fast switching laser. Please pay more attention to PicoLO laser, which has succeeded in commercialization model with stabilized technology.

    2020.11.18

  • LASEROPTEK Co. Ltd., Announces U.S. Launch of PALLAS, First-of-its-Kind Solid State UVB Medical Dermatology Laser

    LASEROPTEK's PALLAS Solid-State 311nm UVB Laser is Clinically- Proven & FDA Cleared to Treat Vitiligo, Psoriasis, Atopic Dermatitis and Leukodermas SEOUL, Republic of Korea, Aug. 12, 2020 /PRNewswire/ -- LASEROPTEK Co., Ltd., a developer and manufacturer of world-class laser devices for aesthetic and medical dermatology, is pleased to announce the launch of its PALLAS Solid-State 311nm UVB laser in the United States.  The efficacious and safe PALLAS laser is FDA cleared for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma. LASEROPTEK's PALLAS Solid-State UVB Laser FDA Cleared For Treating Vitiligo, Psoriasis, Atopic Dermatitis and Leukodermas. Available In 308nm or 311nm Models. Solid-State Design Negates the Need For Costly Gas and Electrode Replacements Driving a Strong Return On Investment. PALLAS is Safe, Efficacious and With a Low Cost of Ownership. PALLAS is the fifth LASEROPTEK laser device to receive FDA clearance in the U.S. for dermatological treatments and brings to the U.S. market the world's first solid-state UVB laser delivering efficacious and safer treatment for a variety of skin conditions that collectively affect close to a billion people worldwide. PALLAS features unique technology improvements over 308 nanometer excimer lasers currently used to treat vitiligo, psoriasis, atopic dermatitis and leukodermas.  PALLAS provides physicians flexibility by allowing the choice of either 308 or 311 nanometer versions.  Both wavelength choices feature PALLAS' unique, solid-state technology eliminating the need for costly and time-consuming excimer gas and electrode replacements no matter which wavelength is chosen.  This reduction in operating costs is a desired and welcomed benefit in today's challenging market environment. Dr. Peter Jenkin, owner of Dermatology Associates of Seattle since 2010, is a respected expert in the treatment of pigmentation related skin disorders and is among the first health care providers offering treatments using PALLAS.  "I chose LASEROPTEK's PALLAS UVB laser with the 311nanometer output option given its efficacy and higher safety profile for my patients.  I had been aware of research for a few years that the 311nm wavelength might be the best option," this according to Dr. Jenkin. "I also appreciate the solid-state technology that negates the need for costly and time-consuming service calls to replace electrodes and excimer gas," added Dr. Jenkin. Commenting on the launch of PALLAS in the U.S., CJ Lee, CEO of LASEROPTEK said, "LASEROPTEK, in collaboration with our U.S. partners Gale Force Aesthetics and Laser Service Solutions, is deeply committed to developing, selling and servicing advanced laser devices to the U.S. medical and cosmetic dermatology market that improve safety, efficacy and economics for our physician customers and their patients.  PALLAS is a great example of this commitment.  We very much appreciate Dr. Jenkin's trust in PALLAS to provide his patients with safe, efficacious and comfortable treatments.  We look forward to a long-term relationship with Dr. Jenkin and the entire staff at Dermatology Associates of Seattle." Jayson Jonsson, CEO of Gale Force Aesthetics, the exclusive distributor of LASEROPTEK lasers in the U.S. adds, "We are excited and proud to partner with LASEROPTEK to launch PALLAS in the U.S.  Physicians need safe and effective treatment options for difficult-to-treat skin conditions like vitiligo, psoriasis, atopic dermatitis and leukodermas. We are confident that this device will provide a much-needed option to physicians and deliver great results for patients." To learn more about LASEROPTEK's world-class lineup of lasers for aesthetic and medical dermatology, please visit www.laseroptek.com.  To purchase or lease a LASEROPTEK laser in the United States, please visit www.galeforceaesthetics.com or contact Jayson Jonsson at +1(925) 705-6206.  To learn more about Dermatology Associates of Seattle's extensive offering of medical and aesthetic treatments, please visit www.daseattle.com or call +1(206) 267-2100. About LASEROPTEK Co., Ltd. LASEROPTEK is a global technology-driven medical device company in the aesthetic and medical laser market. Founded in 2000 and with its in-house R&D capabilities, LASEROPTEK introduces safe, stable and highly efficacious laser systems merging advanced laser technology with clinical efficacy. About Dermatology Associates of Seattle Our mission is to promote optimal health of the skin by providing the highest quality, comprehensive, personalized dermatologic care. Our team members are committed to carrying out this mission in a respectful and enriching work environment that fosters professional development. About Gale Force Aesthetics, LLC Gale Force Aesthetics partners with best-in-class manufacturers – deploying a nationwide team of independent sales consultants that drive sales while building a strong reputation of excellence for their partners. Media Contacts:Helena Lee245160@email4pr.com+82.2.6954.1895 Christopher Dalton245160@email4pr.com+1.619.609.4757 SOURCE LASEROPTEK Co. Ltd. https://www.prnewswire.com/news-releases/laseroptek-co-ltd-announces-us-launch-of-pallas-first-of-its-kind-solid-state-uvb-medical-dermatology-laser-301110706.html

    2020.08.12